Addressing the Complications of Ebola and Other Viral Hemorrhagic Fever Infections: Using Insights from Bacterial and Fungal Sepsis

PLoS Pathogens

Volumn 11, Issue 10, 2015, Pages

  Hellman, Judith ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; CORTICOSTEROID; HAPTOGLOBIN; HEMOGLOBIN; HEMOPEXIN; INTERLEUKIN 6; ROUNDABOUT RECEPTOR; SLIT PROTEIN; TISSUE FACTOR PATHWAY INHIBITOR; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR AGONIST; VASCULAR ENDOTHELIAL CADHERIN;

ADAPTIVE IMMUNITY; ARTICLE; BACTEREMIA; DISSEMINATED INTRAVASCULAR CLOTTING; EBOLA HEMORRHAGIC FEVER; EBOLAVIRUS; FUNGEMIA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; INNATE IMMUNITY; NONHUMAN; PATHOGENESIS; VIRUS HEMORRHAGIC FEVER; VIRUS IMMUNITY; BACTERIAL INFECTION; COMPLICATION; MYCOSIS; SEPSIS;

BACTERIAL INFECTIONS; HEMORRHAGIC FEVER, EBOLA; HEMORRHAGIC FEVERS, VIRAL; HUMANS; MYCOSES; SEPSIS;

EID: 84946099460     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1005088     Document Type: Article

References (69)

1. Team WHOER (2014) Ebola virus disease in West Africa—the first 9 months of the epidemic and forward projections. N Engl J Med 371: 1481–1495. doi: 10.1056/NEJMoa1411100 25244186
2. Team WHOERAgua-Agum J, Ariyarajah A, Aylward B, Blake IM, et al. (2015) West African Ebola epidemic after one year—slowing but not yet under control. N Engl J Med 372: 584–587. doi: 10.1056/NEJMc1414992 25539446
3. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, et al. (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101: 1644–1655. 1303622
4. Hotchkiss RS, Swanson PE, Freeman BD, Tinsley KW, Cobb JP, et al. (1999) Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit Care Med 27: 1230–1251. 10446814
5. Gogos CA, Drosou E, Bassaris HP, Skoutelis A, (2000) Pro- versus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. J Infect Dis 181: 176–180. 10608764
6. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, et al. (2001) Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29: 1303–1310. 11445675
7. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, et al. (2003) 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 31: 1250–1256. 12682500
8. Martin GS, Mannino DM, Eaton S, Moss M, (2003) The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348: 1546–1554. 12700374
9. Levi M, de Jonge E, van der Poll T, (2003) Sepsis and disseminated intravascular coagulation. J Thromb Thrombolysis 16: 43–47. 14760211
10. Kellum JA, Kong L, Fink MP, Weissfeld LA, Yealy DM, et al. (2007) Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. Arch Intern Med 167: 1655–1663. 17698689
11. Rittirsch D, Flierl MA, Ward PA, (2008) Harmful molecular mechanisms in sepsis. Nat Rev Immunol 8: 776–787. doi: 10.1038/nri2402 18802444
12. Schouten M, Wiersinga WJ, Levi M, van der Poll T, (2008) Inflammation, endothelium, and coagulation in sepsis. J Leukoc Biol 83: 536–545. 18032692
13. Kumar P, Shen Q, Pivetti CD, Lee ES, Wu MH, et al. (2009) Molecular mechanisms of endothelial hyperpermeability: implications in inflammation. Expert Rev Mol Med 11: e19. doi: 10.1017/S1462399409001112 19563700
14. Hutchins NA, Unsinger J, Hotchkiss RS, Ayala A, (2014) The new normal: immunomodulatory agents against sepsis immune suppression. Trends Mol Med 20: 224–233. doi: 10.1016/j.molmed.2014.01.002 24485901
15. Mahanty S, Bray M, (2004) Pathogenesis of filoviral haemorrhagic fevers. Lancet Infect Dis 4: 487–498. 15288821
16. Feldmann H, Geisbert TW, (2011) Ebola haemorrhagic fever. Lancet 377: 849–862. doi: 10.1016/S0140-6736(10)60667-8 21084112
17. Sanchez A, Lukwiya M, Bausch D, Mahanty S, Sanchez AJ, et al. (2004) Analysis of human peripheral blood samples from fatal and nonfatal cases of Ebola (Sudan) hemorrhagic fever: cellular responses, virus load, and nitric oxide levels. J Virol 78: 10370–10377. 15367603
18. Rollin PE, Bausch DG, Sanchez A, (2007) Blood chemistry measurements and D-Dimer levels associated with fatal and nonfatal outcomes in humans infected with Sudan Ebola virus. J Infect Dis 196 Suppl 2: S364–371. 17940972
19. Hutchinson KL, Rollin PE, (2007) Cytokine and chemokine expression in humans infected with Sudan Ebola virus. J Infect Dis 196 Suppl 2: S357–363. 17940971
20. McElroy AK, Erickson BR, Flietstra TD, Rollin PE, Nichol ST, et al. (2014) Ebola hemorrhagic Fever: novel biomarker correlates of clinical outcome. J Infect Dis 210: 558–566. doi: 10.1093/infdis/jiu088 24526742
21. Chertow DS, Kleine C, Edwards JK, Scaini R, Giuliani R, et al. (2014) Ebola virus disease in West Africa—clinical manifestations and management. N Engl J Med 371: 2054–2057. doi: 10.1056/NEJMp1413084 25372854
22. Schieffelin JS, Shaffer JG, Goba A, Gbakie M, Gire SK, et al. (2014) Clinical illness and outcomes in patients with Ebola in Sierra Leone. N Engl J Med 371: 2092–2100. doi: 10.1056/NEJMoa1411680 25353969
23. Kreuels B, Wichmann D, Emmerich P, Schmidt-Chanasit J, de Heer G, et al. (2014) A case of severe Ebola virus infection complicated by gram-negative septicemia. N Engl J Med 371: 2394–2401. doi: 10.1056/NEJMoa1411677 25337633
24. Lyon GM, Mehta AK, Varkey JB, Brantly K, Plyler L, et al. (2014) Clinical care of two patients with Ebola virus disease in the United States. N Engl J Med 371: 2402–2409. doi: 10.1056/NEJMoa1409838 25390460
25. Wolf T, Kann G, Becker S, Stephan C, Brodt HR, et al. (2015) Severe Ebola virus disease with vascular leakage and multiorgan failure: treatment of a patient in intensive care. Lancet 385: 1428–1435. doi: 10.1016/S0140-6736(14)62384-9 25534190
26. Ansumana R, Jacobsen KH, Sahr F, Idris M, Bangura H, et al. (2015) Ebola in Freetown area, Sierra Leone—a case study of 581 patients. N Engl J Med 372: 587–588. doi: 10.1056/NEJMc1413685 25539447
27. Escudero-Perez B, Volchkova VA, Dolnik O, Lawrence P, Volchkov VE, (2014) Shed GP of Ebola virus triggers immune activation and increased vascular permeability. PLoS Pathog 10: e1004509. doi: 10.1371/journal.ppat.1004509 25412102
28. Mahanty S, Hutchinson K, Agarwal S, McRae M, Rollin PE, et al. (2003) Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses. J Immunol 170: 2797–2801. 12626527
29. Hotchkiss RS, Karl IE, (2003) The pathophysiology and treatment of sepsis. N Engl J Med 348: 138–150. 12519925
30. Beutler BA, (2009) TLRs and innate immunity. Blood 113: 1399–1407. doi: 10.1182/blood-2008-07-019307 18757776
31. Opitz B, Eitel J, Meixenberger K, Suttorp N, (2009) Role of Toll-like receptors, NOD-like receptors and RIG-I-like receptors in endothelial cells and systemic infections. Thromb Haemost 102: 1103–1109. doi: 10.1160/TH09-05-0323 19967140
32. Baize S, Leroy EM, Georges AJ, Georges-Courbot MC, Capron M, et al. (2002) Inflammatory responses in Ebola virus-infected patients. Clin Exp Immunol 128: 163–168. 11982604
33. Gupta M, Mahanty S, Ahmed R, Rollin PE, (2001) Monocyte-derived human macrophages and peripheral blood mononuclear cells infected with ebola virus secrete MIP-1alpha and TNF-alpha and inhibit poly-IC-induced IFN-alpha in vitro. Virology 284: 20–25. 11352664
34. Hensley LE, Young HA, Jahrling PB, Geisbert TW, (2002) Proinflammatory response during Ebola virus infection of primate models: possible involvement of the tumor necrosis factor receptor superfamily. Immunol Lett 80: 169–179. 11803049
35. Dolnik O, Volchkova V, Garten W, Carbonnelle C, Becker S, et al. (2004) Ectodomain shedding of the glycoprotein GP of Ebola virus. EMBO J 23: 2175–2184. 15103332
36. Yang ZY, Duckers HJ, Sullivan NJ, Sanchez A, Nabel EG, et al. (2000) Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury. Nat Med 6: 886–889. 10932225
37. Basler CF, Mikulasova A, Martinez-Sobrido L, Paragas J, Muhlberger E, et al. (2003) The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. J Virol 77: 7945–7956. 12829834
38. Bosio CM, Aman MJ, Grogan C, Hogan R, Ruthel G, et al. (2003) Ebola and Marburg viruses replicate in monocyte-derived dendritic cells without inducing the production of cytokines and full maturation. J Infect Dis 188: 1630–1638. 14639532
39. Kash JC, Muhlberger E, Carter V, Grosch M, Perwitasari O, et al. (2006) Global suppression of the host antiviral response by Ebola- and Marburgviruses: increased antagonism of the type I interferon response is associated with enhanced virulence. J Virol 80: 3009–3020. 16501110
40. Cardenas WB, Loo YM, Gale M, Jr.Hartman AL, Kimberlin CR, et al. (2006) Ebola virus VP35 protein binds double-stranded RNA and inhibits alpha/beta interferon production induced by RIG-I signaling. J Virol 80: 5168–5178. 16698997
41. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, et al. (2013) Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 41: 580–637. doi: 10.1097/CCM.0b013e31827e83af 23353941
42. Angus DC, (2011) The search for effective therapy for sepsis: back to the drawing board? JAMA 306: 2614–2615. doi: 10.1001/jama.2011.1853 22187284
43. Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. (2009) Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol 19: 12–19. doi: 10.1007/s10165-008-0125-1 18979150
44. Opal SM, Laterre PF, Francois B, LaRosa SP, Angus DC, et al. (2013) Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. JAMA 309: 1154–1162. doi: 10.1001/jama.2013.2194 23512062
45. Spite M, Serhan CN, (2010) Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins. Circ Res 107: 1170–1184. doi: 10.1161/CIRCRESAHA.110.223883 21071715
46. Walker J, Dichter E, Lacorte G, Kerner D, Spur B, et al. (2011) Lipoxin a4 increases survival by decreasing systemic inflammation and bacterial load in sepsis. Shock 36: 410–416. doi: 10.1097/SHK.0b013e31822798c1 21701419
47. Li Y, Dalli J, Chiang N, Baron RM, Quintana C, et al. (2013) Plasticity of leukocytic exudates in resolving acute inflammation is regulated by MicroRNA and proresolving mediators. Immunity 39: 885–898. doi: 10.1016/j.immuni.2013.10.011 24238341
48. Chatterjee A, Sharma A, Chen M, Toy R, Mottola G, et al. (2014) The Pro-Resolving Lipid Mediator Maresin 1 (MaR1) Attenuates Inflammatory Signaling Pathways in Vascular Smooth Muscle and Endothelial Cells. PLoS One 9: e113480. doi: 10.1371/journal.pone.0113480 25409514
49. Fullerton JN, O'Brien AJ, Gilroy DW, (2014) Lipid mediators in immune dysfunction after severe inflammation. Trends Immunol 35: 12–21. doi: 10.1016/j.it.2013.10.008 24268519
50. Buckley CD, Gilroy DW, Serhan CN, (2014) Proresolving lipid mediators and mechanisms in the resolution of acute inflammation. Immunity 40: 315–327. doi: 10.1016/j.immuni.2014.02.009 24656045
51. Nagarkatti P, Pandey R, Rieder SA, Hegde VL, Nagarkatti M, (2009) Cannabinoids as novel anti-inflammatory drugs. Future Med Chem 1: 1333–1349. doi: 10.4155/fmc.09.93 20191092
52. Wilhelmsen K, Khakpour S, Tran A, Sheehan K, Schumacher M, et al. (2014) The endocannabinoid/endovanilloid N-arachidonoyl dopamine (NADA) and synthetic cannabinoid WIN55,212–2 abate the inflammatory activation of human endothelial cells. J Biol Chem 289: 13079–13100. doi: 10.1074/jbc.M113.536953 24644287
53. Tschop J, Kasten KR, Nogueiras R, Goetzman HS, Cave CM, et al. (2009) The cannabinoid receptor 2 is critical for the host response to sepsis. J Immunol 183: 499–505. doi: 10.4049/jimmunol.0900203 19525393
54. Fedson DS, Jacobson JR, Rordam OM, Opal SM, (2015) Treating the Host Response to Ebola Virus Disease with Generic Statins and Angiotensin Receptor Blockers. MBio 6(3):e00716. doi: 10.1128/mBio.00716-15 26106080
55. Thomas G, Hraiech S, Loundou A, Truwit J, Kruger P, et al. (2015) Statin therapy in critically-ill patients with severe sepsis: a review and meta-analysis of randomized clinical trials. Minerva Anestesiol 81(8):921–30. 25690048
56. Deshpande A, Pasupuleti V, Rothberg MB, (2015) Statin therapy and mortality from sepsis: a meta-analysis of randomized trials. Am J Med 128: 410–417 e411. doi: 10.1016/j.amjmed.2014.10.057 25526798
57. Annane D, Sebille V, Charpentier C, Bollaert PE, Francois B, et al. (2002) Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288: 862–871. 12186604
58. Sprung CL, Annane D, Keh D, Moreno R, Singer M, et al. (2008) Hydrocortisone therapy for patients with septic shock. N Engl J Med 358: 111–124. doi: 10.1056/NEJMoa071366 18184957
59. Geisbert TW, Young HA, Jahrling PB, Davis KJ, Kagan E, et al. (2003) Mechanisms underlying coagulation abnormalities in ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event. J Infect Dis 188: 1618–1629. 14639531
60. Geisbert TW, Hensley LE, Jahrling PB, Larsen T, Geisbert JB, et al. (2003) Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet 362: 1953–1958. 14683653
61. Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, et al. (2012) Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 366: 2055–2064. doi: 10.1056/NEJMoa1202290 22616830
62. Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, et al. (2003) Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 290: 238–247. 12851279
63. Dejana E, Orsenigo F, Lampugnani MG, (2008) The role of adherens junctions and VE-cadherin in the control of vascular permeability. J Cell Sci 121: 2115–2122. doi: 10.1242/jcs.017897 18565824
64. London NR, Zhu W, Bozza FA, Smith MC, Greif DM, et al. (2010) Targeting Robo4-dependent Slit signaling to survive the cytokine storm in sepsis and influenza. Sci Transl Med 2: 23ra19. doi: 10.1126/scitranslmed.3000678 20375003
65. Ziegler T, Horstkotte J, Schwab C, Pfetsch V, Weinmann K, et al. (2013) Angiopoietin 2 mediates microvascular and hemodynamic alterations in sepsis. J Clin Invest 123(8):3436–3445.
66. Larsen R, Gozzelino R, Jeney V, Tokaji L, Bozza FA, et al. (2010) A central role for free heme in the pathogenesis of severe sepsis. Sci Transl Med 2: 51ra71. doi: 10.1126/scitranslmed.3001118 20881280
67. Lin T, Sammy F, Yang H, Thundivalappil S, Hellman J, et al. (2012) Identification of hemopexin as an anti-inflammatory factor that inhibits synergy of hemoglobin with HMGB1 in sterile and infectious inflammation. J Immunol 189: 2017–2022. doi: 10.4049/jimmunol.1103623 22772444
68. Arredouani MS, Kasran A, Vanoirbeek JA, Berger FG, Baumann H, et al. (2005) Haptoglobin dampens endotoxin-induced inflammatory effects both in vitro and in vivo. Immunology 114: 263–271. 15667571
69. Gulland A, (2015) Liberia confirms Ebola case two months after being declared free of the disease. BMJ 350: h3620. doi: 10.1136/bmj.h3620 26138714